A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Recruiting

Phase 1

Phase 2

ASP1570, PembrolizumabA Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Sponsor:

Astellas Pharma Global Development, Inc.

Code:

NCT05083481

Conditions

Advanced Solid Tumors

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ASP1570

pembrolizumab

Trifluridine + Tipiracil

Bevacizumab

Docetaxel

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-15. This information was provided to ClinicalTrials.gov by Astellas Pharma Global Development, Inc. on 2026-01-09.